Topical pimecrolimus in the treatment of vitiligo

European Journal of Dermatology

Volumn 17, Issue 1, 2007, Pages 55-61

  Boone, Barbara ^a   Ongenae, Katia ^a   Van Geel, Nanny ^a   Vernijns, Sander ^a   De Keyser, Stefanie ^a   Naeyaert, Jean Marie ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Efficacy; Pimecrolimus; Safety; Topical immunomodulator; Vitiligo

Indexed keywords

PIMECROLIMUS;

ACNE; ADULT; APPLICATION SITE BURNING; ARTICLE; BODY SURFACE; BURNING SENSATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; TREATMENT OUTCOME; VITILIGO;

ADMINISTRATION, TOPICAL; ADULT; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PILOT PROJECTS; PROSPECTIVE STUDIES; TACROLIMUS; VITILIGO;

EID: 33847737004     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: 10.1684/ejd.2007.0093     Document Type: Article

References (51)

1. Nordlund JJ. The epidemiology and genetics of vitiligo. Clin Dermatol 1997; 15: 875-8.
2. Boisseau-Garsaud AM, Saint-Cyr I, Quist D, et al. Familial aggregation of vitiligo in the French West Indies (Isle of Martinique). Eur J Dermatol 2001; 11: 554-6.
3. Kovacs SO. Vitiligo. J Am Acad Dermatol 1998; 38: 647-66; (quiz 67-8).
4. Ongenae K, Beelaert L, van Geel N, et al. Psychosocial effects of vitiligo. J Eur Acad Dermatol Venereol 2006; 20: 1-8.
5. Tjioe M, Vissers WH, Gerritsen MJ. Topical macrolide immunomodulators: a role in the treatment of vitiligo? Am J Clin Dermatol 2006; 7: 7-12.
6. Kostovic K, Pasic A. New treatment modalities for vitiligo: focus on topical immunomodulators. Drugs 2005; 65: 447-59.
7. Issa CM, Rehder J, Taube MB. Melanocyte transplantation for the treatment of vitiligo: effects of different surgical techniques. Eur J Dermatol 2003; 13: 34-9.
8. Plettenberg H, Assmann T, Ruzicka T. Childhood vitiligo and tacrolimus: immunomodulating treatment for an autoimmune disease. Arch Dermatol 2003; 139: 651-4.
9. Hartmann A, Brocker EB, Becker JC. Hypopigmentary skin disorders: current treatment options and future directions. Drugs 2004; 64: 89-107.
10. Grimes PE, Morris R, Avaniss-Aghajani E, et al. Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol 2004; 51: 52-61.
11. Taieb A. Tacrolimus and the pigmentary system. Dermatology 2005; 210: 177-8.
12. Lan CC, Chen GS, Chiou MH, et al. FK506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes: possible mechanisms of how tacrolimus ointment induces repigmentation in patients with vitiligo. Br J Dermatol 2005; 153: 498-505.
13. van Geel N, Ongenae K, De Mil M, et al. Double-blind placebo-controlled study of autologous transplanted epidermal cell suspensions for repigmenting vitiligo. Arch Dermatol 2004; 140: 1203-8.
14. Lepe V, Moncada B, Castanedo-Cazares JP, et al. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol 2003; 139: 581-5.
15. Mayoral FA, Gonzalez C, Shah NS, et al. Repigmentation of vitiligo with pimecrolimus cream: a case report. Dermatology 2003; 207: 322-3.
16. Coskun B, Saral Y, Turgut D. Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo. Eur J Dermatol 2005; 15: 88-91.
17. Passeron T, Ostovari N, Zakaria W, et al. Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo. Arch Dermatol 2004; 140: 1065-9.
18. Kawalek AZ, Spencer JM, Phelps RG. Combined excimer laser and topical tacrolimus for the treatment of vitiligo: a pilot study. Dermatol Surg 2004; 30: 130-5.
19. Ormerod AD. Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern? Br J Dermatol 2005; 153: 701-5.
20. Ring J, Barker J, Behrendt H, et al. Review of the potential photococarcinogenicity of topical calcineurin inhibitors: position statement of the European Dermatology Forum. J Eur Acad Dermatol Venereol 2005; 19: 663-71.
21. Passeron T, Ortonne JP. Use of the 308-nm excimer laser for psoriasis and vitiligo. Clin Dermatol 2006; 24: 33-42.
22. Tran C, LubbeJ, Sorg O, et al. Topical calcineurin inhibitors decrease the production of UVB-induced thymine dimers from hairless mouse epidermis. Dermatology 2005; 211: 341-7.
23. Doelker L, Tran C, Gkomouzas A, et al. Production and clearance of cyclobutane dipyrimidine dimers in UV-irradiated skin pretreated with 1% pimecrolimus or 0.1% triamcinolone acetonide creams in normal and atopic patients. Exp Dermatol 2006; 15: 342-6.
24. Schallreuter KU, Behrens-Williams S, Khaliq TP, et al. Increased epidermal functioning wild-type p53 expression in vitiligo. Exp Dermatol 2003; 12: 268-77.
25. Schallreuter KU, Tobin DJ, Panske A. Decreased photodamage and low incidence of non-melanoma skin cancer in 136 sun-exposed Caucasian patients with vitiligo. Dermatology 2002; 204: 194-201.
26. Sendur NKG, Sanic N, Savk E. Topical pimecrolimus: a new horizon for vitiligo treatment? J Eur Acad Dermatol Venereol 2005; 19: 246; (Poster Presentation).
27. Soter NA, Fleischer Jr AB, Webster GF, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. J Am Acad Dermatol 2001; 44: S39-S46.
28. Gerber PA, Neumann NJ, Ruzicka T, et al. Perioral dermatitis following treatment with tacrolimus. Hautarzt 2005; 56: 967-8.
29. Antille C, Saurat JH, Lubbe J. Induction of rosaceiform dermatitis during treatment of facial inflammatory dermatoses with tacrolimus ointment. Arch Dermatol 2004; 140: 457-60.
30. Crawford KM, Russ B, Bostrom P. Pimecrolimus for treatment of acne rosacea. Skinmed 2005; 4: 147-50.
31. Tan JK, Morneau K, Fung K. Randomized controlled trial of pimecrolimus 1% cream for treatment of facial acne vulgaris. J Am Acad Dermatol 2005; 52: 738-9.
32. Ahn BK, Kim BD, Lee SJ, et al. Molluscum contagiosum infection during the treatment of vitiligo with tacrolimus ointment. J Am Acad Dermatol 2005; 52: 532-3.
33. Hanifin JM, Paller AS, Eichenfield L, et al. Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis. J Am Acad Dermatol 2005; 53: S186-S194.
34. Wolff K. Pimecrolimus 1% cream for the treatment of atopic dermatitis. Skin Therapy Lett 2005; 10: 1-6.
35. Fleischer Jr AB, Ling M, Eichenfield L, et al. Tacrolimus ointment for the treatment of atopic dermatitis is not associated with an increase in cutaneous infections. J Am Acad Dermatol 2002; 47: 562-70.
36. Bieber T, Cork M, Ellis C, et al. Consensus statement on the safety profile of topical calcineurin inhibitors. Dermatology 2005; 211: 77-8.
37. Allen A, Siegfried E, Silverman R, et al. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch Dermatol 2001; 137: 747-50.
38. Qureshi AA, Fischer MA. Topical calcineurin inhibitors for atopic dermatitis: balancing clinical benefit and possible risks. Arch Dermatol 2006; 142: 633-7.
39. Gupta AK, Chow M. Pimecrolimus: a review. J Eur Acad Dermatol Venereol 2003; 17: 493-503.
40. Rikkers SM, Holland GN, Drayton GE, et al. Topical tacrolimus treatment of atopic eyelid disease. Am J Ophthalmol 2003; 135: 297-302.
41. Freeman AK, Serie J, VanVeldhuisen P, et al. Tacrolimus ointment in the treatment of eyelid dermatitis. Cutis 2004; 73: 267-71.
42. Mehrabi D, Pandya AG. A randomized, placebo-controlled, double-blind trial comparing narrowband UV-B Plus 0.1% tacrolimus ointment with narrowband UV-B plus placebo in the treatment of generalized vitiligo. Arch Dermatol 2006; 142: 927-9.
43. Ostovari N, Passeron T, Lacour JP, et al. Lack of efficacy of tacrolimus in the treatment of vitiligo in the absence of UV-B exposure. Arch Dermatol 2006; 142: 252-3.
44. Almeida P, Borrego L, Rodriguez-Lopez J, et al. Vitiligo. Treatment of 12 cases with topical tacrolimus. Actas Dermosifiliogr 2005; 96: 159-63.
45. Kanwar AJ, Dogra S, Parsad D. Topical tacrolimus for treatment of childhood vitiligo in Asians. Clin Exp Dermatol 2004; 29: 589-92.
46. Silverberg NB, Lin P, Travis L, et al. Tacrolimus ointment promotes repigmentation of vitiligo in children: a review of 57 cases. J Am Acad Dermatol 2004; 51: 760-6.
47. Travis LB, Weinberg JM, Silverberg NB. Successful treatment of vitiligo with 0.1% tacrolimus ointment. Arch Dermatol 2003; 139: 571-4; (discussion 3).
48. Castanedo-Cazares JP, Lepe V, Moncada B. Repigmentation of chronic vitiligo lesions by following tacrolimus plus ultraviolet-B-narrow-band. Photodermatol Photoimmunol Photomed 2003; 19: 35-6.
49. Tanghetti EA. Tacrolimus ointment 0.1% produces repigmentation in patients with vitiligo: results of a prospective patient series. Cutis 2003; 71: 158-62.
50. Grimes PE, Soriano T, Dytoc MT. Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol 2002; 47: 789-91.
51. Smith DA, Tofte SJ, Hanifin JM. Repigmentation of vitiligo with topical tacrolimus. Dermatology 2002; 205: 301-3.